160 related articles for article (PubMed ID: 30112336)
1. Efficacy and safety of nimotuzumab in unresectable, recurrent, and/or metastatic squamous cell carcinoma of the head and neck: A hospital-based retrospective evidence.
Subramanian S; Sridharan N; Balasundaram V; Chaudhari S
South Asian J Cancer; 2018; 7(3):188-192. PubMed ID: 30112336
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of nimotuzumab with concurrent chemoradiotherapy in unresectable locally advanced squamous cell carcinoma of head and neck: An Indian rural hospital experience.
Rawat S; Tandan H; Patel S; Chaudhari S
South Asian J Cancer; 2019; 8(1):52-56. PubMed ID: 30766856
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and tolerability of nimotuzumab in unresectable, locally advanced/metastatic esophageal cancer: Indian hospital-based retrospective evidence.
Subramanian S; Sridharan N; Balasundaram V; Chaudhari S
South Asian J Cancer; 2019; 8(2):112-115. PubMed ID: 31069192
[TBL] [Abstract][Full Text] [Related]
4. Nimotuzumab with intensity-modulated radiation therapy in unresectable and platinum-ineligible locally advanced head-and-neck cancer.
Srinivas KS; Sundaram R; Divyambika CV; Chaudhari S
South Asian J Cancer; 2020; 9(1):43-46. PubMed ID: 31956621
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of concurrent chemoradiotherapy with or without Nimotuzumab in unresectable locally advanced squamous cell carcinoma of head and neck: Prospective comparative study - ESCORT-N study.
Kumar A; Chakravarty N; Bhatnagar S; Chowdhary GS
South Asian J Cancer; 2019; 8(2):108-111. PubMed ID: 31069191
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of nimotuzumab in combination with chemotherapy in recurrent and metastatic squamous cell carcinoma of head and neck at a cancer center in Northern India.
Yadav A; Goyal P; Agrawal CR; Bothra SJ; Jain P; Choudhury KD; Gupta SK; Sharma M; Bajaj R; Upadhyay A; Dash P; Doval DC
Indian J Cancer; 2020; 57(1):76-83. PubMed ID: 32129298
[TBL] [Abstract][Full Text] [Related]
7. Tislelizumab plus nimotuzumab is effective against recurrent or metastatic oral squamous cell carcinoma among patients with a performance status score ≥ 2: a retrospective study.
Wu WJ; An PG; Zhong YW; Hu X; Wang L; Zhang J
Front Oncol; 2023; 13():1273798. PubMed ID: 38293699
[TBL] [Abstract][Full Text] [Related]
8. Combined Nimotuzumab with Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma.
Thai Hoa NT; Quang Huy H
Cureus; 2020 May; 12(5):e8105. PubMed ID: 32426197
[TBL] [Abstract][Full Text] [Related]
9. Addition of Nimotuzumab to Standard TPF Regimen in Locally Advanced Head and Neck Cancer: A Single Institutional Study.
Koramati SL; Sarathy V; Varayathu H; Thomas BE; Naik R
J Oncol; 2021; 2021():6641963. PubMed ID: 33953747
[TBL] [Abstract][Full Text] [Related]
10. Clinical effectiveness of 125I-seed implantation in combination with nimotuzumab therapy for the advanced oral carcinoma: preliminary results.
Meng J; Wang X; Zhuang QW; Gu QP; Zhang J; Li ZP
Eur Rev Med Pharmacol Sci; 2014; 18(21):3304-10. PubMed ID: 25487943
[TBL] [Abstract][Full Text] [Related]
11. Nimotuzumab combined with radiotherapy for the treatment of hypopharyngeal cancer - A case report from a tertiary cancer center.
Nagarajan A; Sakthivelu A; Santhanaraman N; Ravichandar R
J Clin Transl Res; 2021 Apr; 7(2):285-288. PubMed ID: 34104833
[TBL] [Abstract][Full Text] [Related]
12. Combined nimotuzumab with chemoradiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma: A retrospective study.
Lai X; Gu Q; Zheng X; Liu G; Feng W; Lin X; Mao W
J Cancer Res Ther; 2016 Oct; 12(Supplement):89-95. PubMed ID: 27721263
[TBL] [Abstract][Full Text] [Related]
13. Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open-label, phase IIb, 5-year study in Indian patients.
Reddy BK; Lokesh V; Vidyasagar MS; Shenoy K; Babu KG; Shenoy A; Naveen T; Joseph B; Bonanthaya R; Nanjundappa ; Bapsy PP; Loknatha ; Shetty J; Prasad K; Tanvir Pasha CR
Oral Oncol; 2014 May; 50(5):498-505. PubMed ID: 24613543
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02).
Tahara M; Kiyota N; Yokota T; Hasegawa Y; Muro K; Takahashi S; Onoe T; Homma A; Taguchi J; Suzuki M; Minato K; Yane K; Ueda S; Hara H; Saijo K; Yamanaka T
Ann Oncol; 2018 Apr; 29(4):1004-1009. PubMed ID: 29408977
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.
Cripps C; Winquist E; Devries MC; Stys-Norman D; Gilbert R;
Curr Oncol; 2010 Jun; 17(3):37-48. PubMed ID: 20567625
[TBL] [Abstract][Full Text] [Related]
16. Real-World Experience of Immunotherapy from India in Recurrent Squamous Cell Carcinoma of Head and Neck Cancer.
Abbas W; Gupta S; Goel V; Rao RR; Pankaj P; Tripathi D; Patil PP; Popli S
South Asian J Cancer; 2021 Apr; 10(2):72-75. PubMed ID: 34568218
[No Abstract] [Full Text] [Related]
17. Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck.
Trieu V; Pinto H; Riess JW; Lira R; Luciano R; Coty J; Boothroyd D; Colevas AD
Oncologist; 2018 Jul; 23(7):764-e86. PubMed ID: 29540603
[TBL] [Abstract][Full Text] [Related]
18. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy and safety of neoadjuvant toripalimab combined with nimotuzumab and chemotherapy in patients with unresectable stage Ⅳ squamous cell carcinoma of penis].
Yan R; Guo SJ; An X; Jiang LJ; Liu TY; Xue T; Ma HL; Yao K; Shi YX; Han H
Zhonghua Wai Ke Za Zhi; 2022 Dec; 60(12):1093-1099. PubMed ID: 36480877
[No Abstract] [Full Text] [Related]
20. Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: A single centre prospective phase II trial.
Lu M; Wang X; Shen L; Jia J; Gong J; Li J; Li J; Li Y; Zhang X; Lu Z; Zhou J; Zhang X
Cancer Sci; 2016 Apr; 107(4):486-90. PubMed ID: 26797530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
